The purpose of this research is to investigate the impact of hydroxychloroquine on the incidence of hypertensive pregnancy disorders in women with a history of recurrent spontaneous abortion (RSA).
Preeclampsia affects about 3-5% of all pregnancies and is estimated to cause at least 42 000 maternal deaths annually, remaining an important cause of death and complications for the mother and baby. However, no treatment yet has been found that affects disease progression except for termination of pregnancy which may cause iatrogenic preterm labor. Therefore, keenly sought for approaches to improving clinical outcomes in pre-eclampsia would be needed. Hydroxychloroquine (HCQ), an antimalarial drug, is commonly used in the treatment of pregnant women with RSA and has proven to be safe for both the mother and the fetus. Because of the antioxidant effect, anti-inflammatory effect, and vasculoprotective effect of HCQ, it has been thought to be beneficial in the prevention of preeclampsia. Therefore, we conducted a retrospective cohort study to evaluate the impact of HCQ treatment on the prevention of preeclampsia in RSA pregnancies.
Study Type
OBSERVATIONAL
Enrollment
462
Hydroxychloroquine was administered during pregnancy
Shanghai Jiao Tong University School of Medicine，Renji Hospital
Shanghai, Shanghai Municipality, China
Composite morbidity
Preeclampsia, gestational hypertension, preeclampsia superimposed upon chronic hypertension
Time frame: Gestational period
fetal growth restriction
\<10th percentile for gestational age
Time frame: 37 weeks of gestational age
Preterm delivery
Delivery before 37 weeks
Time frame: 37 weeks of gestational age
Abruptio placenta
The number of cases of abruptio placenta that appear in both groups at any given time during pregnancy
Time frame: 37 weeks of gestational age
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.